Isoprenoid pathway inhibitors for stimulating cartilage growth
    4.
    发明申请
    Isoprenoid pathway inhibitors for stimulating cartilage growth 审中-公开
    用于刺激软骨生长的异戊二醛途径抑制剂

    公开(公告)号:US20050272801A1

    公开(公告)日:2005-12-08

    申请号:US11167054

    申请日:2005-06-24

    摘要: Compounds of the formula wherein X in each of formulas (1) and (2) represents a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6C; Y is of the formula or a stereoisomer thereof, wherein R1 is substituted or unsubstituted alkyl; each R2 is independently H, hydroxy, alkoxy (1-6C) or lower alkyl (1-4C); R3 is H, hydroxy, or alkoxy (1-6C); or Y is of the formula wherein each n is 1, Z is N, K comprises a substituted or unsubstituted aromatic carbocyclic or heterocyclic ring system which may optionally be spaced from the linkage position shown in formula (7) by a linker of 1-2C, or in formula (7), Z may be spaced from the carbon bonded to X by ═CR6— wherein R6 is H or linear, branded or cyclic alkyl (1-6C), R5 is H or linear, branched or cyclic alkyl, and R′ represents a cation, H or a substituted or unsubstituted alkyl group of 1-6C, promote bone formation and are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation. Also disclosed is a method to identify additional compounds which are inhibitors of enzymes in the isoprenoid scheme especially of HMG-CoA reductase which results in prenylation of proteins and in the synthesis of steroids or of inhibitors of their production which are useful in treating bone disorders.

    摘要翻译: 式(1)和(2)中的X表示取代或未取代的2-6C的亚烷基,亚烯基或亚炔基接头; Y是下式或其立体异构体,其中R 1是取代或未取代的烷基; 每个R 2独立地是H,羟基,烷氧基(1-6C)或低级烷基(1-4C); R 3是H,羟基或烷氧基(1-6C); 或Y具有下式:其中每个n是1,Z是N,K包括取代或未取代的芳族碳环或杂环系统,其可以任选地与式(7)所示的连接位置间隔1-2- ,或式(7)中,Z可以与通过-CR 6键合到X的碳隔开,其中R 6是H或直链的,有品牌的或环状的烷基( 1-6C)中,R 5是H或直链,支链或环状的烷基,R'表示阳离子,H或1-6C的取代或未取代的烷基,促进骨形成,因此 可用于治疗骨质疏松症,骨折或缺陷,原发性或继发性甲状旁腺功能亢进,牙周病或缺损,转移性骨病,溶骨性骨病,整形外手术,假体后关节手术和牙后植入术。 还公开了一种鉴定另外的化合物的方法,该化合物是类异戊二烯方案中尤其是HMG-CoA还原酶中的酶的抑制剂,其导致蛋白质的异戊烯化,以及合成类固醇或其生产抑制剂,其可用于治疗骨骼疾病。

    Conformationally constrained parathyroid hormone (pth) analogs
    6.
    发明申请
    Conformationally constrained parathyroid hormone (pth) analogs 有权
    构象约束甲状旁腺激素(pth)类似物

    公开(公告)号:US20050026839A1

    公开(公告)日:2005-02-03

    申请号:US10484080

    申请日:2002-07-19

    申请人: Thomas Gardella

    发明人: Thomas Gardella

    CPC分类号: C07K14/635 A61K38/00

    摘要: The present invention relates to conformationally constrained parathyroid hormone (PTH) analogs, and methods of preparing and using the PTH analogs. The invention provides novel PTH polypeptide derivatives containing amino acid substitutions at selected positions in the polypeptides. The invention provides derivatives of PTH (1-34), PTH(1-21), PTH(1-20), PTH(1-19), PTH(1-18), PTH(1-17), PTH(1-16), PTH(1-15), PTH(1-14), PTH(1-13), PTH(1-12), PTH(1-11) and PTH(1-1 0) polypeptides, wherein at least one residue in each polypeptide is a helix, preferably an a-helix, stabilizing residue. The invention also provides methods of making such peptides. Further, the invention encompasses compositions and methods for use in limiting undesired bone loss in a vertebrate at risk of such bone loss, in treating conditions that are characterized by undesired bone loss or by the need for bone growth, e.g. in treating fractures or cartilage disorders and for raising cAMP levels in cells where deemed necessary.

    摘要翻译: 本发明涉及构象约束的甲状旁腺激素(PTH)类似物,以及制备和使用PTH类似物的方法。 本发明提供了在多肽的选定位置含有氨基酸取代的新型PTH多肽衍生物。 本发明提供了PTH(1-34),PTH(1-21),PTH(1-20),PTH(1-19),PTH(1-18),PTH(1-17),PTH -16),PTH(1-15),PTH(1-14),PTH(1-13),PTH(1-12),PTH(1-11)和PTH(1-10)多肽,其中 每个多肽中的至少一个残基是螺旋,优选α-螺旋的稳定残基。 本发明还提供了制备这些肽的方法。 此外,本发明包括用于限制在具有这种骨丢失风险的脊椎动物中不期望的骨丢失的组合物和方法,在治疗以不期望的骨丢失为特征的病症中,或通过对骨生长的需要。 在治疗骨折或软骨障碍并提高认为必要的细胞中的cAMP水平。

    Use of Epothilone Derivatives for the Treatment of Hyperparathyroidism
    8.
    发明申请
    Use of Epothilone Derivatives for the Treatment of Hyperparathyroidism 审中-公开
    使用埃坡霉素衍生物治疗甲状旁腺功能亢进

    公开(公告)号:US20110152329A1

    公开(公告)日:2011-06-23

    申请号:US13037989

    申请日:2011-03-01

    IPC分类号: A61K31/427 A61P5/20 A61P35/00

    CPC分类号: A61K31/427

    摘要: The present invention relates to a method of treating a warm-blooded animal, especially a human, having hyperparathyroidism comprising administering to said animal a therapeutically effective amount of an epothilone derivative of formula I or a pharmaceutically acceptable salt thereof.

    摘要翻译: 本发明涉及治疗具有甲状旁腺功能亢进的温血动物,特别是人的方法,其包括向所述动物施用治疗有效量的式I埃坡霉素衍生物或其药学上可接受的盐。